SCHEMBL7400521

SCHEMBL7400521

NC(=O)c1ccc2c(c1)CCOO2

nearest known ligand 0.54

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.54
PRKCI P41743 1/20 0.47
KDM1A O60341 2/20 0.41
HTR1A P08908 1/20 0.39
HTR1D P28221 1/20 0.39
HTR2C P28335 1/20 0.39
NPC1 O15118 3/20 0.39
RAB9A P51151 3/20 0.39
TAS1R3 Q7RTX0 2/20 0.39
TAS1R1 Q7RTX1 2/20 0.39
SIRT2 Q8IXJ6 2/20 0.38
CTNNB1 P35222 1/20 0.38
WNT3A P56704 1/20 0.38
HSD17B3 P37058 1/20 0.38
CASP3 P42574 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
SENP7 Q9BQF6 1/20 0.37
LCK P06239 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28071044 0.86 ALDH1A1 (0.49) TSHRPRKCINPC1RAB9ATAS1R3
SCHEMBL8553457 0.85 KDM4E (0.49) TSHRPRKCINPC1RAB9ATAS1R3
SCHEMBL27392330 0.85 PRKCI (0.42) TSHRPRKCINPC1RAB9ATAS1R3
SCHEMBL528982 0.84 TSHR (0.51) TSHRPRKCIKDM1AHTR1AHTR1D
SCHEMBL29503137 0.82 PRKCI (0.69) TSHRPRKCINPC1RAB9ATAS1R3
SCHEMBL2176489 0.82 PRKCI (0.69) TSHRPRKCINPC1RAB9ATAS1R3
SCHEMBL28882612 0.81 CA12 (0.44) TSHRPRKCINPC1RAB9ATAS1R3
Hydrochloric Acid SCHEMBL28130087 0.81 PRKCI (0.67) TSHRPRKCINPC1RAB9ATAS1R3
SCHEMBL10992434 0.79 RAB9A (0.51) PRKCINPC1RAB9ACTNNB1WNT3A
SCHEMBL8319676 0.78 PRKCI (0.63) TSHRPRKCINPC1RAB9ATAS1R3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2002072567-A2 HETEROCYCLIC COMPOUNDS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM GLENMARK PHARMACEUTICALS LIMITED (IN) 2002-09-19 WO claimed
US-9850276-B2 Bidentate-binding modulators of LRRK2 and JNK kinases THE SCRIPPS RESEARCH INSTITUTE (US) 2017-12-26 US disclosed
US-20160185818-A1 BIDENTATE-BINDING MODULATORS OF LRRK2 AND JNK KINASES UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED 2016-06-30 US disclosed
EP-3003302-A1 BIDENTATE-BINDING MODULATORS OF LRRK2 AND JNK KINASES The Scripps Research Institute (US) 2016-04-13 EP disclosed
WO-2014200682-A1 BIDENTATE-BINDING MODULATORS OF LRRK2 AND JNK KINASES THE SCRIPPS RESEARCH INSTITUTE (US) 2014-12-18 WO disclosed
WO-2002072567-A2 HETEROCYCLIC COMPOUNDS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM GLENMARK PHARMACEUTICALS LIMITED (IN) 2002-09-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160185818-A1 BIDENTATE-BINDING MODULATORS OF LRRK2 AND JNK KINASES LRRK2, PINK1, MAP2K3 TSHR 3523/4885PRKCI 430/4885KDM1A 3330/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.